TICKERNERD
Menu
ICCMICCMHealthcare · Medical Devices

ICCM Stock Forecast: IceCure Medical Ltd. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.87
−9.08% on the day

The 3 Wall Street analysts covering IceCure Medical Ltd. hold a median 12-month price target of $28 — +3118.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$4.0M
Ticker Nerd rank
42/ 100
Median analyst target
$28
Analysts covering
3
Revenue$907K+72.8% y/y
Operating income−$4.4M
Net income−$4.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.9%
1M
−46.1%
YTD
−95.2%
1Y
−95.9%
From 52W high
−96.0%
From 52W low
0.0%
$1
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICCM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IceCure Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Growth
90
Revisions
63
Issuance
63
Volatility
39
Accruals
38
Momentum
24
Quality
10
Value
1

Size (97): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ICCM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICCM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26ICCMHigh $30Median $28Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $28High $30

The green dot is the last close — the median target sits +3118.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Maxim GroupMaintainsBuy$3.00 → $1.00
7 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Sept 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024Alliance Global PartnersMaintainsBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
5 Mar 2024HC Wainwright & Co.ReiteratesBuy—
29 Nov 2023HC Wainwright & Co.ReiteratesBuy$3.00
6 Sept 2023HC Wainwright & Co.ReiteratesBuy$3.00
15 Aug 2023Alliance Global PartnersMaintainsBuy$4.25 → $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ICCM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ICCM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, IceCure Medical Ltd. returned −95.9% against +12.4% for the S&P 500, dividends included.

ICCM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ICCMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICCM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

IceCure Medical Ltd. (ICCM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
1.0×

Cheaper than 67% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
0.5×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
72.8%

Higher than 90% of US stocks

Earnings growth (YoY)
72.8%

Higher than 80% of US stocks

Gross margin
27.9%

Higher than 31% of US stocks

Operating margin
−487.8%

Higher than 8% of US stocks

Net margin
36.3%

Higher than 93% of US stocks

Returns & dividend
Return on equity
−228.3%

Higher than 6% of US stocks

Return on assets
−73.9%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IceCure Medical Ltd. (ICCM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IceCure Medical Ltd. has a market value of $4.0M and an enterprise value of −$8.7M.

  • Revenue in the twelve months to 30 June 2026: $3.9M. The latest quarter grew 72.8% year on year.

  • Net income over the same four quarters: −$16.9M, a −427.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$15.9M.

  • Shares outstanding: 3.4M.

  • Trailing P/E: −0.1×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • IceCure Medical Ltd. employs 67 people — $59K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

ICCM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ICCMIceCure Medical Ltd.$4.0M42
NUWENuwellis, Inc.$3.1M15
AIDX20/20 Biolabs, Inc.$2.8M3
CODXCo-Diagnostics, Inc.$3.2M39
POASPhaos Technology Holdings (Cayman) Ltd.$2.7M2
AMIXAutonomix Medical, Inc.$3.5M27
BJDXBluejay Diagnostics, Inc.$2.5M20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IceCure Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICCM news & analysis

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

PRNewsWire · 27 Oct 2026positive

IceCure Medical reported that the first patient in its ChoICE post-marketing study was treated at West Cancer Center in Tennessee. The study is evaluating ProSense cryoablation for local treatment of low-risk breast cancer.

Why it matters — The treatment marks the study’s first patient milestone for ICCM’s evaluation of ProSense in breast cancer.

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

PRNewsWire · 20 Oct 2026positive

IceCure Medical announced that the first two patients have been enrolled at two U.S. clinical sites in the ChoICE post-marketing study evaluating ProSense cryoablation for local treatment of low-risk breast cancer.

Why it matters — The enrollment marks the start of patient participation at the study’s U.S. sites, providing an update on the evaluation of ProSense for breast cancer treatment.

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

PRNewsWire · 13 Oct 2026positive

IceCure said ProSense® breast cancer cryoablation was featured in scientific presentations, research posters and physician workshops at the EUSOBI 2026 Annual Scientific Meeting in Maastricht. The company described physician engagement across Europe as strong.

Why it matters — The event’s presentations and workshops provide ICCM watchers with an update on the visibility of ProSense® among European physicians.

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

PRNewsWire · 6 Oct 2026positive

IceCure Medical announced that Legacy Health in Portland, Oregon, including Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center, has joined as a U.S. clinical site for its post-marketing ChoICE Study evaluating ProSense cryoablation for local treatment of low-risk breast cancer.

Why it matters — The addition expands the study’s U.S. clinical-site network for evaluating ProSense in low-risk breast cancer.

IceCure Secures China NMPA Approval for ProSense Cryoablation System

Zacks Investment Research · 11 Sept 2026positive

IceCure Medical Ltd. received approval from China's NMPA for its ProSense cryoablation system, enabling commercialization of the product in China. The approval expands the company's global regulatory footprint and opens a new long-term market opportunity.

Why it matters — This approval gives IceCure access to the Chinese market for ProSense, broadening its revenue potential and strengthening its international regulatory standing.

FAQ

Frequently asked questions about ICCM stock

What is the ICCM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering IceCure Medical Ltd. have a median 12-month price target of $28, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICCM stock a buy right now?

Of the 3 analysts covering IceCure Medical Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IceCure Medical Ltd. 42 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICCM?

As at 31 Oct 2026, IceCure Medical Ltd. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will ICCM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +3118.0% from the last close, and Ticker Nerd's factor model ranks IceCure Medical Ltd. 42 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICCM stock forecast for 2030?

No analyst covering IceCure Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

How has ICCM stock performed over the past year?

IceCure Medical Ltd. returned -95.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IceCure Medical Ltd. do?

IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment.

What is the latest news on ICCM?

The most recent item we track (PRNewsWire, 27 Oct 2026): "IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation". IceCure Medical reported that the first patient in its ChoICE post-marketing study was treated at West Cancer Center in Tennessee. The study is evaluating ProSense cryoablation for local treatment of low-risk breast cancer.

Company

About IceCure Medical Ltd.

IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment. Its core products use liquid nitrogen-based technology to destroy benign and cancerous tumors by freezing them, offering physicians an alternative to traditional surgical removal. The company’s portfolio includes the ProSense system and associated disposable CryoProbes, which are used in procedures across women’s health and interventional oncology. IceCure Medical also supports broader ablation applications in areas such as breast, kidney, bone, and lung cancer, with products designed for use in office-based, operating room, and imaging-guided settings. Based in Caesarea, Israel, IceCure Medical serves healthcare providers in multiple international markets and plays a niche role in expanding access to minimally invasive tumor care.

CEO Mr. Eyal Shamir · 67 employees · Israel · https://www.icecure-medical.com